• 1\. Age ≥18 years. 2. Patient must have confirmation of AML based on 2016 World Health Organization (WHO) criteria and not been previously treated.

• 3\. Patients must have CD123-positive AML as confirmed by local flow cytometry (or immunohistochemistry \[IHC\]). Confirmation at diagnosis is acceptable.

• 4\. Patient must be considered ineligible for induction therapy defined by at least one of the following:

⁃ ≥75 years of age

⁃ Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3

⁃ Cardiac disorder (e.g., congestive heart failure requiring treatment, ejection fraction ≤ 50%, or chronic stable angina)

⁃ Pulmonary disorder (e.g., DLCO ≤65% or FEV1 ≤65%)

⁃ Creatinine clearance 30-45 mL/min based on Cockcroft-Gault or Modified of Diet in Renal Disease (MDRD) formular

⁃ Hepatic disorder with total bilirubin between 1.5 and 3 times the ULN 5. Patient must have a projected life expectancy of ≥12 weeks